The company is already manufacturing some doses of the vaccine. 💉 engineering
, Pfizer CEO Albert Bourla said that the company's Omicron-specific vaccine would be ready in March, even though he wasn't sure whether a variant-specific vaccine was needed or how it would be used.
that the vaccines would protect against severe disease and death, they weren't so sure about their ability to reduce symptomatic infection. as early as 8 December 2021 showed that the Omicron variant could evade the neutralizing antibodies that were expected to block the virus in the early stages of infection. This set us on the path of booster doses that increased the levels of neutralizing antibodies to combat the new COVID variant.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer CEO says omicron vaccine will be ready in March
Read more »
Pfizer says its vaccine targeting Omicron will be ready in MarchDrugmaker expects to be able to develop new variant-specific vaccines in roughly 100 days as COVID-19 mutates.
Read more »
Omicron-specific vaccines could be ready by March. Will we need them?Covid vaccines targeted to the omicron variant could be ready by March.
Read more »
Pfizer: Omicron-specific COVID-19 vaccine human trials to begin late JanuaryPfizer confirmed it plans to start human trials of its omicron-specific COVID-19 vaccine later this month, potentially making it available to the public as soon as March.
Read more »
Omicron-Specific Vaccine Is Coming But ‘May Not Matter—Everybody's Going to Be Infected,' Says ExpertBoth Pfizer and Moderna have omicron-specific vaccines coming. But the targeted shot was needed in December to help stem the current wave, say experts.
Read more »
AirAsia CEO says international travel will bounce back strongly despite omicron impactInternational travel is likely to recover soon despite the progress being slowed by the omicron variant, according to AirAsia chief executive Tony Fernandes.
Read more »